Pharma company has offered to supply its messenger RNA (mRNA) vaccine to the Indian government at a “not-for-profit” price as part of its strategy of adopting a distinct pricing structure for different countries.
“For India, Pfizer has offered a not-for-profit price for its vaccine for the government immunization programme. We continue to be in discussions with the government and remain committed to make our vaccine available for deployment in India’s immunization programme,” the company spokesperson said in a statement on Thursday.
For now, co intends to supply only to govt, not in open market
The company’s statement follows news reports, which cited prices for American vaccines.According to the US-based company it has adopted a distinct pricing structure.
“This would be our approach in India as well. Further, in all our agreements Pfizer has adopted a distinct pricing structure for high, middle, and low/lower-middle-income countries consistent with our commitment to work towards equitable and affordable access for our covid-19 vaccine for people around the world,” the company said.
The company did not disclose the price structure as yet.
In the US, the company is charging $19.5 per dose from the government to supply the vaccine.